Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Rating of “Moderate Buy” from Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $8.00.

QNCX has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Quince Therapeutics in a research report on Monday. D. Boral Capital lifted their price target on shares of Quince Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Monday. Finally, Zacks Research raised shares of Quince Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th.

Quince Therapeutics Stock Up 0.5%

QNCX stock opened at $3.72 on Thursday. Quince Therapeutics has a 52-week low of $0.72 and a 52-week high of $4.55. The firm has a market cap of $207.13 million, a P/E ratio of -3.07 and a beta of 1.03. The company’s 50-day simple moving average is $2.45 and its 200-day simple moving average is $1.89.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.05). On average, analysts anticipate that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in Quince Therapeutics in the 2nd quarter valued at about $37,000. GSA Capital Partners LLP increased its stake in Quince Therapeutics by 158.0% during the 3rd quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock worth $142,000 after buying an additional 53,417 shares in the last quarter. Bridgeway Capital Management LLC raised its holdings in shares of Quince Therapeutics by 20.9% during the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after acquiring an additional 22,200 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new position in shares of Quince Therapeutics in the second quarter valued at approximately $280,000. Finally, Union Square Park Capital Management LLC lifted its position in shares of Quince Therapeutics by 86.0% in the third quarter. Union Square Park Capital Management LLC now owns 224,746 shares of the company’s stock valued at $366,000 after acquiring an additional 103,889 shares in the last quarter. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.